Clinical Trial Update: Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of HS110 vaccine in combination with Erlotinib for non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• HS110 vaccine

Snippet

Sponsor: Heat Biologics | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN